JP2020510443A - 細胞ゲノムにおける、相同組換え修復(hdr)の効率を上昇させるための方法 - Google Patents

細胞ゲノムにおける、相同組換え修復(hdr)の効率を上昇させるための方法 Download PDF

Info

Publication number
JP2020510443A
JP2020510443A JP2019554497A JP2019554497A JP2020510443A JP 2020510443 A JP2020510443 A JP 2020510443A JP 2019554497 A JP2019554497 A JP 2019554497A JP 2019554497 A JP2019554497 A JP 2019554497A JP 2020510443 A JP2020510443 A JP 2020510443A
Authority
JP
Japan
Prior art keywords
hdr
cell
nuclease
cells
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019554497A
Other languages
English (en)
Japanese (ja)
Inventor
ジョン・ネイサン・フェダー
チィ・グオ
ガブリエル・アレン・ミンティア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61006349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2020510443(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2020510443A publication Critical patent/JP2020510443A/ja
Priority to JP2023176087A priority Critical patent/JP2024009934A/ja
Priority to JP2025174888A priority patent/JP2026012785A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2019554497A 2016-12-20 2017-12-20 細胞ゲノムにおける、相同組換え修復(hdr)の効率を上昇させるための方法 Pending JP2020510443A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023176087A JP2024009934A (ja) 2016-12-20 2023-10-11 細胞ゲノムにおける、相同組換え修復(hdr)の効率を上昇させるための方法
JP2025174888A JP2026012785A (ja) 2016-12-20 2025-10-16 細胞ゲノムにおける、相同組換え修復(hdr)の効率を上昇させるための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437042P 2016-12-20 2016-12-20
US62/437,042 2016-12-20
PCT/US2017/067569 WO2018119060A1 (en) 2016-12-20 2017-12-20 Methods for increasing the efficiency of homology directed repair (hdr) in the cellular genome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023176087A Division JP2024009934A (ja) 2016-12-20 2023-10-11 細胞ゲノムにおける、相同組換え修復(hdr)の効率を上昇させるための方法

Publications (1)

Publication Number Publication Date
JP2020510443A true JP2020510443A (ja) 2020-04-09

Family

ID=61006349

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019554497A Pending JP2020510443A (ja) 2016-12-20 2017-12-20 細胞ゲノムにおける、相同組換え修復(hdr)の効率を上昇させるための方法
JP2023176087A Pending JP2024009934A (ja) 2016-12-20 2023-10-11 細胞ゲノムにおける、相同組換え修復(hdr)の効率を上昇させるための方法
JP2025174888A Pending JP2026012785A (ja) 2016-12-20 2025-10-16 細胞ゲノムにおける、相同組換え修復(hdr)の効率を上昇させるための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023176087A Pending JP2024009934A (ja) 2016-12-20 2023-10-11 細胞ゲノムにおける、相同組換え修復(hdr)の効率を上昇させるための方法
JP2025174888A Pending JP2026012785A (ja) 2016-12-20 2025-10-16 細胞ゲノムにおける、相同組換え修復(hdr)の効率を上昇させるための方法

Country Status (7)

Country Link
US (2) US20230193321A1 (cg-RX-API-DMAC7.html)
EP (2) EP3559230B1 (cg-RX-API-DMAC7.html)
JP (3) JP2020510443A (cg-RX-API-DMAC7.html)
KR (2) KR20230162134A (cg-RX-API-DMAC7.html)
CN (2) CN118460529A (cg-RX-API-DMAC7.html)
ES (1) ES2962711T3 (cg-RX-API-DMAC7.html)
WO (1) WO2018119060A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2021251493A1 (cg-RX-API-DMAC7.html) * 2020-06-12 2021-12-16

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
WO2016073990A2 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
CA2999500A1 (en) 2015-09-24 2017-03-30 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
WO2017165826A1 (en) 2016-03-25 2017-09-28 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
US11236313B2 (en) 2016-04-13 2022-02-01 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
CN118460529A (zh) 2016-12-20 2024-08-09 百时美施贵宝公司 提高细胞基因组中同源定向修复(hdr)效率的方法
EP3652312A1 (en) 2017-07-14 2020-05-20 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
US11952408B2 (en) * 2017-10-03 2024-04-09 Juno Therapeutics, Inc. HPV-specific binding molecules
EP3820503A4 (en) * 2018-07-13 2022-07-13 Allele Biotechnology & Pharmaceuticals, Inc. METHODS FOR HIGH SPECIFICITY GENOME EDITING
EP3994258A4 (en) 2019-07-03 2022-10-26 Integrated Dna Technologies, Inc. IDENTIFICATION, CHARACTERIZATION AND QUANTIFICATION OF DOUBLE-STRAND DNA BREAK REPAIR INTRODUCED BY CRISPR
CA3154370A1 (en) * 2019-10-24 2021-04-29 Jessica WOODLEY Modified double-stranded donor templates
CN111549052A (zh) * 2020-05-07 2020-08-18 西南大学 一种真核生物CRISPR/Cas全基因组编辑载体文库及构建方法
CN111944847A (zh) * 2020-08-28 2020-11-17 西北农林科技大学 一套等位基因高效替换系统及其建立方法
CN113416730B (zh) * 2021-07-07 2023-04-04 中国医学科学院血液病医院(中国医学科学院血液学研究所) 一种降低细胞因基因编辑产生的大片段删除突变的方法
GB202117455D0 (en) * 2021-12-02 2022-01-19 Academisch Ziekenhuis Leiden Method of editing nucleic acid

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110129898A1 (en) * 2009-05-18 2011-06-02 Yannick Doyon Methods and compositions for increasing nuclease activity
WO2016154579A2 (en) * 2015-03-26 2016-09-29 Editas Medicine, Inc. Crispr/cas-mediated gene conversion
WO2016182959A1 (en) * 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
CA2186118C (en) 1994-03-23 2010-10-19 Richard W. Hanson Compacted nucleic acids and their delivery to cells
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
WO2012012738A1 (en) * 2010-07-23 2012-01-26 Sigma-Aldrich Co., Llc Genome editing using targeting endonucleases and single-stranded nucleic acids
EP4019635A1 (en) 2015-03-25 2022-06-29 Editas Medicine, Inc. Crispr/cas-related methods, compositions and components
CN107787367B (zh) 2015-04-06 2021-10-26 里兰斯坦福初级大学理事会 用于crispr/cas介导的基因调控的化学修饰的引导rna
US10179918B2 (en) 2015-05-07 2019-01-15 Sangamo Therapeutics, Inc. Methods and compositions for increasing transgene activity
CN105734032A (zh) * 2016-03-25 2016-07-06 扬州大学 一种山羊blg基因定点敲除修饰系统及应用
CN118460529A (zh) 2016-12-20 2024-08-09 百时美施贵宝公司 提高细胞基因组中同源定向修复(hdr)效率的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110129898A1 (en) * 2009-05-18 2011-06-02 Yannick Doyon Methods and compositions for increasing nuclease activity
WO2016154579A2 (en) * 2015-03-26 2016-09-29 Editas Medicine, Inc. Crispr/cas-mediated gene conversion
WO2016182959A1 (en) * 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DOYON Y. ET AL.: "Transient cold shock enhances zinc-finger nuclease-mediated gene disruption", NATURE METHODS, vol. ADVANCE ONLINE PUBLICATION, JPN6022004317, 2010, pages 1 - 3, ISSN: 0004701624 *
ELIFE, vol. Vol.3, e04766, JPN6022050551, 2014, pages 1 - 13, ISSN: 0004931610 *
NUCLEIC ACIDS RESEARCH, vol. 41, no. 19, JPN6022050550, 2013, pages 9049 - 9061, ISSN: 0004931611 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2021251493A1 (cg-RX-API-DMAC7.html) * 2020-06-12 2021-12-16
WO2021251493A1 (ja) * 2020-06-12 2021-12-16 国立研究開発法人産業技術総合研究所 卵白タンパク質遺伝子における目的タンパク質をコードする遺伝子がノックインされた家禽細胞またはその製造方法

Also Published As

Publication number Publication date
CN118460529A (zh) 2024-08-09
CN110300803B (zh) 2024-05-14
EP4286523A3 (en) 2024-03-20
KR20190095412A (ko) 2019-08-14
EP3559230A1 (en) 2019-10-30
EP4286523A2 (en) 2023-12-06
ES2962711T3 (es) 2024-03-20
EP3559230B1 (en) 2023-09-06
US20230193321A1 (en) 2023-06-22
JP2026012785A (ja) 2026-01-27
US20260132427A1 (en) 2026-05-14
JP2024009934A (ja) 2024-01-23
KR20230162134A (ko) 2023-11-28
WO2018119060A1 (en) 2018-06-28
CN110300803A (zh) 2019-10-01

Similar Documents

Publication Publication Date Title
US20260132427A1 (en) Methods for increasing the efficiency of homology directed repair (hdr) in the cellular genome
JP6993063B2 (ja) ゲノムエンジニアリング
CN115651927B (zh) 编辑rna的方法和组合物
US10557151B2 (en) Somatic human cell line mutations
Guo et al. ‘Cold shock’increases the frequency of homology directed repair gene editing in induced pluripotent stem cells
US12065667B2 (en) Modified Cpf1 MRNA, modified guide RNA, and uses thereof
Byrne et al. Genome editing in human stem cells
CN116209755A (zh) 可编程核酸酶和使用方法
JP2019193679A (ja) 造血幹細胞におけるヌクレアーゼ媒介性ゲノム工学および補正のための方法および組成物
CA3009727A1 (en) Compositions and methods for the treatment of hemoglobinopathies
WO2017216771A2 (en) Crispr-cas system, materials and methods
JP2017536811A (ja) 多能性細胞の樹立又は維持のための方法及び組成物
EP3274453A2 (en) Crispr/cas-mediated gene conversion
JP2017517250A (ja) 標的エンドヌクレアーゼを用いる哺乳類ゲノムのエピジェネティック修飾
JP7210028B2 (ja) 遺伝子変異導入方法
CN113423831A (zh) 核酸酶介导的重复扩增
JP2024501892A (ja) 新規の核酸誘導型ヌクレアーゼ
WO2024182440A2 (en) Methods and compositions for modifying nucleotide sequences
HK40081918B (en) Methods and compositions for editing rna
HK40112369A (en) Engineered high fidelity omni-50 nuclease variants

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220506

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230613